On Sept. 16, 2021, Celsion and Hainan Poly Pharm announced an amendment to their existing contract manufacturing agreement to include development work for Celsionﾒs investigational DNA-based COVID-19 vaccine.

Under the terms of the amended agreement, Poly Pharm will manufacture clinical batches and, if approved for use, will also manufacture commercial batches for Celsionﾒs vaccine based on its TheraPlas technology.